Xdynia is a preclinical pharmaceutical company that develops drugs that block Cav3.2 for the prevention and treatment of neuropathic pain.
Chronic pain affects 76.2 million Americans with only 40% reporting partial relief of symptoms. Whether from diabetes, shingles, fibromyalgia, cancer, HIV, trauma, or phantom limb, the Cav3.2 T-channel is a common pathway in its development.
Our library of Cav3.2 inhibitors comes from the minds and labs of the world's experts in Cav3.2. These compounds are undergoing preclinical studies.